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Abstract: The main aim of this study was the analysis of undifferentiated cancers and mixed ones positive for
neuroendocrine biomarkers without morphological features — typical for this type of cancer. The obtained
results indicated the necessity for neuroendocrine marker tests in undifferentiated cancers and mixed ones.
Immunopositive results revealed enhanced malignancy of these cancers and the necessity for additional chemo-
therapy. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 2, 280–285)
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Introduction
Besides the endocrine system, the human body is
equipped with a heterogenic group of neuroendocrine
cells (Diffuse Endocrine System — DES) distributed
all over the organism. The ‘APUD cell’ (amine-pre-
cursor uptake and decarboxylation system) hypothe-
sis formulated by Pearse says that these cells are not
only able to gather amines, but can also uptake amine
precursors and transform them into amines through
the intracellular decarboxylation process [1]. Two types
of secretory granules were isolated from the cytoplasm
of neuroendocrine cells: big granules with electron-
dense material in the core part, and microvesicles sim-
ilar to presynaptic vesicles of the nervous system
[1, 2]. They ectopically produce endocrine non-hormonal
biomarkers, biogenic amines and various polypeptide
hormones [3–6]. In the endometrium, pure neuroen-
docrine cancers are very rare, and are more frequently
recognized in the ovaries and uterine cervix [7–12].
Recently, articles have been published about the
coexistence of undifferentiated cancers, serous and
endometrioid, with focal positive immunoreactions
for one or more neuroendocrine markers without
morphological transformation into neuroendocrine
cancer [5, 13–17]. This phenomenon is not well known
and needs additional studies.
The aim of this study was to assess neuroendo-
crine cells in endometrial cancers with regard to their
number, origin, localization and morphological pic-
ture. The obtained results were related to the type of
cancer, the degree of differentiation, and the stage of
development. Additionally, the effect of neuroendo-
crine markers on cancer malignancy in the presence
of immunopositive cells was determined.
Material and methods
Twenty endometrial cancers including three undifferentiat-
ed cancers (G3), two serous carcinoma (G2), three partial-
ly undifferentiated partially endometrioid carcinoma, and
12 endometrioid adenocarcinoma (seven in G1 and five in
G2 stage) were studied. In all patients, a uterectomy with
uterine adnexa was carried out; lymphadenectomy of the
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pelvis was done in two patients. In some patients, radio-
therapy was applied and, additionally, chemotherapy was
included in three other patients. The characteristics of the
study group are set out in Table 1.
In addition, three normal fetal uterus, five normal en-
dometrium (two secretory, three proliferative phase) and
four endometrium with pathological hyperplasia were stud-
ied. In all the 20 cancerous and additionally collected mate-
rial, immunohistochemical analysis was done for the pres-
ence of neuroendocrine markers such as chromogranin A,
synaptophysin and neuron-specific enolase (NSE). Moreover,
staining for the presence of progesterone receptor (PR),
which determines the degree of differentiation of endometri-
oid cancers, was done. In addition, staining for cytokeratin
(AE1/AE3), vimentin, CD117, and desmin was carried out.
Immunoreaction was carried out with the horseradish per-
oxidase (HRP) system, EnVisionTM+ (Dako, Poland).
Some antibodies (Dako, Poland) were used in the fol-
lowing dilutions: 1:50 vimentin, 1:200 NSE, 1:400 CD117.
Remaining antibodies were bought in ready-to-use concen-
trations. Anti-chromogranin A, anti-synaptophysin and anti-
CD117 antibodies were polyclonal, and the remaining anti-
bodies were monoclonal. The negative control was the omis-
sion of the first antibody. In the assessment of neuroendo-
crine markers expression, an additional control was tissue
section from endocrinal carcinoma positive for three neu-
romarkers.
Results
Five out of eight low-differentiated cancers needed
special attention. Those cancers were placed in the
first five positions in Tables 1 and 2. The first of them
(No. 1) was diagnosed as adenocarcinoma endometri-
oides partim solidum. In H + E staining, this well-
-differentiated endometrioid cancer included almost
the whole endometrium (60% of tumor area), whereas
undifferentiated solid pattern infiltrated muscle wall
of uterus. Metastasis to lymph nodes only consisted
of undifferentiated solid constitutions, and embolism
from these cells occurred in vessels. In immunohis-
tochemical staining, cancer infiltrating myometrium
was immunopositive for all neuroendocrine markers;
whereas in endometrioid structure, positive reaction
was found only in single multi-cell nests (Figure 1).
Immunopositive reaction for PR was negative in un-
differentiated cancer and strongly positive in en-
dometrioid adenocarcinoma.
In the second case (No. 2), two pictures were ob-
served: solid undifferentiated contained 30% of the
tumor area, while the remaining 70% was represent-
ed by endometrial carcinoma. Solid growth pattern
mainly infiltrated muscle wall of uterus; however, solid
and glandular structures were observed more often
in single focus compared to tumor No. 1. Poorly dif-
ferentiated types were immunopositive for chromog-
ranin A and synaptophysin, and negative for NSE
(Figure 2). Progesterone receptor was stained posi-
tively in adenocarcinomatoid typing. Carcinoma soli-
dum undifferentiatum was diagnosed in cancers
No. 3 and 4. In both cancers, positive reaction for three
neuroendocrine markers was observed. However, in
cancer No. 3, the reaction occurred only in single cells
spread throughout the whole tumor; the highest posi-
tive focus did not exceed 1.0–2.0 mm. In cancer No. 4,
immunopositive reactions contained areas exceeding
as much as 0.5–1.5 cm. Both cancers were negative
for PR. In the histological picture, huge attention was
concentrated on cellular atypia, high mitotic activity,
infiltration of vessels as well as extensive necrosis.
Table 1. Immunohistochemical staining profile for eight studied cancers
Cancer type Cytokeratin Vimentin Chromogranin Synaptophysin NSE PR CD117 Desmin
AE1/AE3
1. Undifferentiated 40% – – + + + + + + + – –
Endometrioid 60% + + – – – +++ –
2. Undifferentiated 30% + – + + + – – –
Endometrioid 70% + – – – – + + –
3. Undifferentiated + – + + + + + + + – – –
4. Undifferentiated + – + + + + + + + – –
5. Serous + – + + – – + –
6. Undifferentiated + – – – – + –
7. Undifferentiated 40% + – – – – – – –
Endometrioid 60% + – – – – ++ –
8. Serous + – – – – + –
+ + + strong expression; + + intermediate expression; + weak expression
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Cancer No. 5 is represented by serous cancer infil-
trating the whole wall of uterus as far as serous mem-
brane. Numerous emboli from cancer cells were visi-
ble in vascular lumen. In immunohistochemical stain-
ing, a high expression of chromogranin A was ob-
served in foci infiltrating uterus wall and in vascular
lumen, whereas immunoreaction was significantly
weaker in the remaining pattern. Two remaining neu-
roendocrine markers were negative. Immunoreaction
for the presence of progesterone receptor occurred
focally, and only in a small number of cells localized
in foci of infiltration.
In three other cancers (Nos. 6, 7, 8) neuroendo-
crine markers were not observed. In the remaining
12 endometrioid moderately differentiated and high-
ly-mature cancers, the presence of disseminated en-
docrine cells of APUD type was noted. They demon-
strated only positive reaction on chromogranin A.
They were located in a basal part of glandular cells or
the immunopositive material was localized in an api-
cal part of glandular cells (Figure 3).
In pathological hyperplasia of endometrium, 1–3
chromogranin positive cells were observed for ten
small magnifications, while in normal and fetal en-
dometrium it was 0–1.
In fetal uterus, single epithelial cells were immu-
nopositive only for chromogranin A.
Discussion
The degree of differentiation of endometrioid cancers
is considered to be one of the key prognostic factors.
Five-year survival rate of women with G1 cancer being
in I° progression is estimated at 92.1%, G2 at 87.5%
and G3 at 74.5% [18]. The less differentiated the cancer
and the deeper the infiltration of the uterus wall, the
poorer the prognosis. Poorly differentiated and undif-
ferentiated endometrial cancers comprise 2% of all en-
dometrial cancers and frequently create mixed cell pop-
ulations with different prognoses [3, 5, 13–16, 19].
In our studies, immunopositive reactions were re-
corded for three neuroendocrine markers in five out
Table 2. Characteristics of studied cancers
No Age Cancer type Differentiation Stage Metastasis to nodes Treatment Survival
“G” (months)
1. 63 Undifferentiated 40% 3 IIIc + RTG 6
Endometrioid 60% 1 – Chemotherapy dead
2. 57 Undifferentiated 30% 3 Ic – RTG 18
Endometrioid 70% 2 relapse in lungs
3. 49 Undifferentiated 3 IIb – RTG 8
4. 58 Undifferentiated 3 IIb – Chemotherapy 1
5. 61 Serous 2 IIa – RTG 10
6. 79 Undifferentiated 3 IIIa – RTG 3
7. 59 Undifferentiated 40% 3 Ib – RTG 1
Endometrioid 60% 1
8. 71 Serous 2 IIIa – RTG 51
Chemotherapy
9. 64 Endometrioid 2 IIIa + RTG 4
dead
10. 58 Endometrioid 1 Ic – – 5
11. 78 Endometrioid 1 Ic – – 4
12. 48 Endometrioid 2 Ib – RTG 6
13. 57 Endometrioid 1 Ia – – 5
14. 60 Endometrioid 2 IIb – RTG 5
15. 60 Endometrioid 2 IIIa – RTG 4
16. 48 Endometrioid 1 IIb – – 7
17. 52 Endometrioid 1 Ia – – 7
18. 60 Endometrioid 1 Ib – – 5
19. 61 Endometrioid 1 Ib – – 5
20. 53 Endometrioid 1 Ib – – 7
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of eight undifferentiated cancers and with mixed cell
population. The remaining three cancers were neu-
roendocrine negative. Therefore, a question appears
as to how we should interpret these cancers, espe-
cially as a prognostic factor. A large heterogeneity
between undifferentiated cancers causes serious di-
agnostic and therapeutic problems since they contain
cancers of differing aetiology. Lung or cervical small-
cell carcinoma with neuroendocrine differentiation
are considered as aggressive carcinomas. It might be
assumed that neuroendocrine differentiation is a po-
tential marker for aggressiveness. Recently, more at-
tention has been concentrated on the fact that un-
differentiated endometrial carcinomas can possess
immunopositive reactions for neuroendocrine mark-
ers without typical morphological features of neuroen-
docrine carcinoma [5, 14, 17]. Tamura et al. showed
Figure 2. Undifferentiated cancer immunoreaction for
synaptophysin (magnification × 250)
Figure 1. Cancer with two different patterns (position
No. 1 in Tables). Solid undifferentiated pattern infiltrating
muscle wall of uterus, H + E staining (A); Following
sections stained for synaptophysin (B); Endometrioid
portion, H + E staining (C); Following section stained for
synaptophysin (D). Nest of cells and single cell immunopo-
sitively stained (arrow) (magnification × 150)
Figure 3. Cells DES type in endometrial carcinoma,
positive for chromogranin A. Localized in glandular basal
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positive reactions for neuroendocrine markers at 63%
of undifferentiated cancers without typical morpho-
logical features [14]. In immunoreaction, single cells
localized in nests were stained or reaction had diffu-
sion character.
In our material, one out of two serous carcinomas
was diffusion stained for the presence of chromogra-
nin A with increased expression in foci of infiltrates
of muscle wall, and negative for the remaining two
markers. However, in two other undifferentiated can-
cers, all three neuroendocrine markers were positive.
Their morphological picture indicated high histolog-
ical malignancy, but was not typical for neuroendo-
crine cancers. However, in two mixed cancers, neu-
roendocrine solid pattern with atypical structure for
this type of cancer deeply infiltrated uterus muscle
wall; endometrioid pattern constitutions were limit-
ed to the endometrium. Similar morphological pic-
tures have been frequently described in the literature
[4, 5, 13, 14, 18, 20, 21]. Histogenesis of such cancer
pattern is not clear. There is no consensus as to wheth-
er they are two independent cancers, or we are wit-
nessing a cancer with mixed cell population. The small
foci of neuroendocrine carcinomas localized within
endometrial carcinoma, and clinical studies exclud-
ing cancer outside the uterus, give the answer as mixed
cell carcinoma. It has been suggested that populations
of both cell types have originated from the same stem
cell [22]. Cancer stem cells go through asymmetrical
division, which induces tumorogenesis from one side
and, from the other, some number of progenitor cells
keep the ability to differentiate and mature, provid-
ing phenotypic heterogeneity. Therefore, various
clones of cancer cells can, in different ways, be phe-
notypically shaped dependent on various pathologi-
cal signal pathways and genetic programs. This phe-
nomenon also seems to explain the occurrence of
positive neuro-immunoreactions in cells, which mor-
phologically did not fit for neuroendocrine cells. It
could be that changes related to morphological trans-
formations did not follow cell biochemistry.
The three commonly used neuroendocrine biom-
arkers for isolated neuroendocrine cancers have dif-
ferent specificities. Synaptophysin is an integral mem-
brane glycoprotein isolated from presynaptic vesicles
and is considered as a very sensitive and specific neu-
roendocrine marker [23]. Chromogranin A, marker
of neuroendocrine granules according to Parka et al.,
and Hamady et al., is a very sensitive marker of neu-
roendocrine cells [24, 25]. Aguirre et al. and Scully et
al., isolated three types of granules in those carcino-
mas, two types with neuroendocrine character and the
third type was connected with the secretion of
polypeptide hormones (calcitonin, gastrin, somatosta-
tin, ACTH, neurotensin and others) [3, 6]. NSE,
a cytosolic marker, is a neural form of glycolytic en-
zymes and is positive in most neuroendocrine carci-
nomas. Nesland et al. demonstrated that positive im-
munoreaction for NSE does not always demonstrate
the real presence of neuroendocrine cells [26]. Due
to various specificities of neuroendocrine markers, it
seems that recognition of that type of cancer should
be supported by at least two additional immunohis-
tochemical tests.
In the 12 endometrioid cancers we examined, the
presence of neuroendocrine cells immunopositive only
on chromogranin A was noted, and they were includ-
ed to DES. They did not form cancer nests, but were
individually incorporated in epithelium of cancer glan-
dular cells (Figure 3). Similar cells were found in nor-
mal endometrium, in pathological hyperplasia and in
endometrium of fetal uterus. These are the same cells
of APUD type, which in older papers were identified
using silver impregnation (the Grimelius method). The
presence of similar cells with similar localization has
been described by numerous authors (27).
Aguirre et al. studied those cells immunohis-
tochemically and by using an electron microscope.
They demonstrated some interdependence between
silver-stained granules and the presence of glycogen
grains or mucin. For example, treatment of tissue
slides with diastase caused the disappearance of gly-
cogen and argyrophilia [3].
This is the first paper in the Polish literature dem-
onstrating material about endometrial cancers. It con-
cerns undifferentiated cancers and mixed cancers
positive for neuroendocrine markers without a typi-
cal morphological pattern. This phenomenon needs
further study on a larger amount of material and with
more precise biological analysis. The presented re-
sults do not allow the drawing of overall conclusions.
These results indicate the necessity to determine
neuroendocrine biomarkers by the immunohis-
tochemical method in undifferentiated and mixed
endometrial cancers. Immunopositive results indicate
a higher malignancy of those cancers, and a necessity
to expand treatment by chemotherapy.
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